Trichome Analytical Appoints Industry Leader Sarah Ahrens as Partner and President, Strengthening Commitment to Cannabis Quality and Transparency

1 year ago

MOUNT LAUREL, NJ / ACCESSWIRE / August 23, 2024 / Trichome Analytical, a leading provider of cannabis testing and compliance…

Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)

1 year ago

CAMBRIDGE, MA / ACCESSWIRE / August 23, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has…

OKYO Pharma CEO Interview to Air on Bloomberg TV

1 year ago

LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing…

CytoDyn Engages Leading CRO For Phase II Inflammation Trial

1 year ago

VANCOUVER, Washington, Aug. 23, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab,…

WORK Medical Technology Group LTD Announces Pricing of Initial Public Offering

1 year ago

Hangzhou, China, Aug. 23, 2024 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (the "Company"), a supplier of medical devices…

European Commission approves BALVERSA®▼ (erdafitinib) for adult patients with unresectable or metastatic urothelial carcinoma

1 year ago

First pan FGFR kinase inhibitor to be approved in the European Economic Area, for adults with unresectable or metastatic urothelial…

Repligen Corporation to Present at Wells Fargo Healthcare Conference

1 year ago

WALTHAM, Mass., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership,…

Tinley’s Provides Update on Upsized Non-Brokered Private Placement and Expanded Debt Settlement with an Anticipated Aggregate Value of up to $8.3 Million

1 year ago

Toronto, Ontario and Los Angeles, California--(Newsfile Corp. - August 23, 2024) - The Tinley Beverage Company Inc. (CSE: TNY) (OTCQB:…

Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna’s COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1

1 year ago

CAMBRIDGE, MA / ACCESSWIRE / August 23, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has received approval from…